Alteogen and Becton Dickinson to Present "Large-Volume Subcutaneous Injection Technology" at Conference
Animal Study Results of 10mL Subcutaneous Injection Using ALT-B4 Platform Revealed
Alteogen announced on March 30 that it will present the results of its joint research on a large-volume subcutaneous injection device with the U.S. medical device company Becton Dickinson (BD) at an international conference in May.
The presentation will take place at "PDA Miniverse 2026," which will be held in Dublin, Ireland, from May 21 to 22. The two companies will disclose the results of animal studies in which the hyaluronidase-based platform "ALT-B4" was used to deliver a 10mL volume via subcutaneous injection.
This study compared and evaluated injection speed, required time, and injection site characteristics depending on whether ALT-B4 was applied. The company explained that the technology demonstrates the potential to improve the efficiency of subcutaneous delivery for large-volume biopharmaceuticals.
Alteogen places significance on having validated the scalability of high-volume drug administration by combining BD's drug delivery devices, such as wearable injectors, with its own platform. The company also noted that, as development of high-volume biopharmaceuticals such as monoclonal and bispecific antibodies expands, the importance of related delivery technologies is increasing.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Alteogen has signed multiple agreements with global partners regarding the development of subcutaneous injection formulations based on its Hybrozyme platform. Since the beginning of this year, the company has continued its collaborations with GSK and Biogen, further expanding the range of platform applications.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.